SerOptix
Inc. is a biotechnology company located in Woburn, Massachusetts
engaged in the exploitation of variations of natural fluorescence
to identify novel disease-specific molecular targets.
Despite
the great advances in medical science during the past several
decades, it is recognized that further improvement in the diagnosis
and treatment of disease is still possible and needed. Future
break-through therapeutic products are likely to be directed to
an entirely new set of biological targets that will be derived
from advanced research in human genomics and proteomics, and the
emerging field of 'chemical genomics'. As powerful strategy for
identifying novel chemical and protein variants in disease, SerOptix'
proprietary technology is well positioned to produce substantial
contributions to this search for new biological targets.
SerOptix
has established a proprietary technology for molecular target
identification that identifies unique disease signatures based
on the intrinsic fluorescence properties of disease-related molecules.
Our platform technology: Spectra-Molecular
Informatics or 'SMI,' combines
advanced spectroscopy, biochemistry and informatics technologies
to obtain, compile and interpret complex molecular signatures.
The Company has successfully applied this technology to the characterization
of the intrinsic fluorescence of molecules derived from human
plasma, and has identified spectra-molecular signatures of potential
importance for new diagnostic product development and for the
identification of disease-specific molecular targets for both
diagnostic or pharmaceutical development.
SerOptix
is advancing its system development efforts to establish a comprehensive
molecular profiling system for the parallel application to multiple
disease targets in important medical markets, as well as for high-value
quality assurance opportunities and other industrial applications.
The Company plans to generate revenues through the establishment
of contracts to define molecular targets for drug discovery and
diagnostic products based on its proprietary SMI technology. The
Company is refining an intrinsic fluorescence-based assay for
the detection of hepatitis C viral (HCV) infection in blood, which
has confirmed the feasibility of SerOptix' strategy, and represents
an early product candidate of potential interest to major pharmaceutical
partners. SerOptix' first Molecular Targets are also correlated
with hepatitis C infection, and demonstrate the power of the SMI
approach for the systematic identification of new targets. The
Company is continuing to build its core technology to further
enhance the Spectra-Molecular-Informatics Platform and effectively
apply fluorescence-based molecular profiling to drug discovery
and diagnostic product development.
The
Company plans to execute the following strategy:
- Further enhance its intrinsic fluorescence-based Spectra-Molecular
Informatics (SMI) platform to permit its efficient application
and creation of a comprehensive normal database.
- Apply SMI to the identification of molecular markers for
multiple disease candidates, including specific degenerative
& metabolic diseases and cancers.
- Establish a portfolio of partner funded R&D programs and
molecular targets to and generate early project revenues.
- Further increase shareholder value by creating a portfolio
of higher value proprietary molecular targets for sale, out-licensing
or formation of joint ventures.
- Complement revenues derived through the Company's target
discovery strategy with subscription-based revenue built on
the value of its proprietary databases.
- Expand the research and development capacity of the Company
to enhance SerOptix' ability to identify and acquire high value
complementary technologies, and sustain productive academic
and business partnerships to maintain a growing asset and product
base.
- Continue to aggressively build an intellectual property portfolio
that protects the Company's innovations. The Company currently
holds two issued U.S. Patents as well as the rights to several
additional U.S. applications covering specific methodologies
and fundamental concepts of SMI that are pending. Specific patents
covering specific disease-related molecules and procedures identified
through SMI will be filed as the discrete elements of intellectual
property suitable for sale or licensing.
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
